Life science heads Danish R&D efforts
Despite being the industry with the highest amount of spending on research and development in the country, sales of novel, patented drugs only account for a fraction of total sales for Danish life science companies, and that is a huge problem, says The Danish Association of the Pharmaceutical Industry (LIF).
Danish life science is the industry that puts the largest amount of funds into research and development measured by net-turnover. The biotech, pharmaceutical and medtech industries spend 20.9 %, 14.8 % and 6.1 % respectively of their net-turnover on R&D, which puts them way ahead of other industries in Denmark.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
